Related Experiment Video
Updated: Jul 7, 2026
Establishment of an Experimental Mouse Model of Endometrioma to Study its Related Infertility
Published on: April 5, 2024
Serum soluble CD163 and interleukin-6 levels in women with ovarian endometriomas
Byung Chul Jee1, Chang Suk Suh, Seok Hyun Kim
1Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea.
Insights
Serum levels of soluble CD163 (sCD163) and interleukin-6 (IL-6) do not effectively distinguish ovarian endometriomas from other benign ovarian cysts. These markers are not recommended for diagnosing endometriosis-related ovarian cysts.
Area of Science:
- Gynecology
- Oncology
- Immunology
Background:
- CD163 is a hemoglobin scavenger receptor on monocytes/macrophages.
- Soluble CD163 (sCD163) has not been evaluated as a serum marker for endometriosis.
- Endometriosis diagnosis can be challenging, necessitating reliable biomarkers.
Purpose of the Study:
- To investigate serum sCD163 and IL-6 as potential biomarkers for ovarian endometriomas.
- To differentiate ovarian endometriomas from other benign adnexal cystic tumors.
Main Methods:
- Quantified sCD163 and IL-6 in serum from 95 women using ELISA.
- Included patients with ovarian endometriomas and other benign cystic tumors.
- Recorded preoperative CA-125 levels and endometrioma cyst volume.
Main Results:
- Serum sCD163 and IL-6 levels showed no significant differences between endometriomas and other benign cysts.
- No correlation found between marker levels and endometrioma volume.
- sCD163 levels were 3,431.7 +/- 343.9 ng/ml in endometriomas vs. 3,231.0 +/- 391.7 ng/ml in others.
- IL-6 levels were 5.3 +/- 0.9 pg/ml in endometriomas vs. 12.9 +/- 4.0 pg/ml in others.
Conclusions:
- Serum sCD163 and IL-6 are not effective biomarkers for diagnosing ovarian endometriomas.
- These markers cannot differentiate endometriomas from other benign adnexal cystic tumors.
Background:
CD163 is a hemoglobin scavenger receptor exclusively expressed in the monocyte-macrophage system and its soluble form (sCD163) has not yet been studied as a serum marker in women with endometriosis. The purpose of this study was to evaluate whether serum levels of sCD163 and interleukin-6 (IL-6) could be possible markers for ovarian endometriomas discriminating adnexal benign cystic tumors.
Methods:
The concentrations of sCD163 and IL-6 were determined using commercial ELISA kits in frozen sera collected from 95 women prior to surgery for adnexal benign cystic tumors: 44 with ovarian endometriomas, 24 with mature cystic teratomas, 10 with mucinous cystadenomas, 8 with serous cystadenomas and 9 with parovarian cysts. Serum levels of CA-125 were also recorded preoperatively. The volume of cysts was evaluated in women with ovarian endometriomas.
Results:
The serum levels of sCD163 and IL-6 were not significantly different among the women with various adnexal benign cystic tumors. In patients with endometriomas (n = 44), the levels were similar to those with nonendometriotic benign cystic tumors (n = 51): 3,431.7 +/- 343.9 vs. 3,231.0 +/- 391.7 ng/ml for sCD163 and 5.3 +/- 0.9 vs. 12.9 +/- 4.0 pg/ml for IL-6 (mean +/- SEM). No correlation was noted between serum levels of two markers with volume of endometriomas.
Conclusion:
Our findings suggest that serum levels of sCD163 as well as IL-6 are not useful markers for ovarian endometriomas.
